Journal article icon

Journal article

Association of prolactin receptor (PRLR) variants with prolactinomas

Abstract:
Prolactinomas are the most frequent type of pituitary tumors, which represent 10–20% of all intracranial neoplasms in humans. Prolactinomas develop in mice lacking the prolactin receptor (PRLR), which is a member of the cytokine receptor superfamily that signals via Janus kinase-2-signal transducer and activator of transcription-5 (JAK2-STAT5) or phosphoinositide 3-kinase-Akt (PI3K-Akt) pathways to mediate changes in transcription, differentiation and proliferation. To elucidate the role of the PRLR gene in human prolactinomas, we determined the PRLR sequence in 50 DNA samples (35 leucocytes, 15 tumors) from 46 prolactinoma patients (59% males, 41% females). This identified six germline PRLR variants, which comprised four rare variants (Gly57Ser, Glu376Gln, Arg453Trp and Asn492Ile) and two low-frequency variants (Ile76Val, Ile146Leu), but no somatic variants. The rare variants, Glu376Gln and Asn492Ile, which were in complete linkage disequilibrium, and are located in the PRLR intracellular domain, occurred with significantly higher frequencies (P < 0.0001) in prolactinoma patients than in 60 706 individuals of the Exome Aggregation Consortium cohort and 7045 individuals of the Oxford Biobank. In vitro analysis of the PRLR variants demonstrated that the Asn492Ile variant, but not Glu376Gln, when compared to wild-type (WT) PRLR, increased prolactin-induced pAkt signaling (>1.3-fold, P < 0.02) and proliferation (1.4-fold, P < 0.02), but did not affect pSTAT5 signaling. Treatment of cells with an Akt1/2 inhibitor or everolimus, which acts on the Akt pathway, reduced Asn492Ile signaling and proliferation to WT levels. Thus, our results identify an association between a gain-of-function PRLR variant and prolactinomas and reveal a new etiology and potential therapeutic approach for these neoplasms.
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1093/hmg/ddy396

Authors


More by this author
Institution:
University of Oxford
Division:
Medical Sciences Division
Department:
RDM
Oxford college:
Exeter College
Role:
Author
More by this author
Institution:
University of Oxford
Division:
Medical Sciences Division
Department:
RDM
Sub department:
OCDEM
Role:
Author
More by this author
Institution:
University of Oxford
Division:
Medical Sciences Division
Department:
RDM
Sub department:
OCDEM
Role:
Author
More by this author
Institution:
University of Oxford
Division:
Medical Sciences Division
Department:
RDM
Sub department:
OCDEM
Role:
Author


More from this funder
Funding agency for:
Thakker, R
Grant:
Senior Investigator Award (R.V.T.
More from this funder
Grant:
106995/Z/15/Z
Senior Investigator Award (R.V.T.
Funding agency for:
Thakker, R
More from this funder
Grant:
Fellowship SCAF/15/01 (P.J.N.
More from this funder
Grant:
G1000467/2010toC.M.G.,P.J.N.
R.V.T


Publisher:
Oxford University Press
Journal:
Human Molecular Genetics More from this journal
Volume:
28
Issue:
6
Pages:
1023–1037
Publication date:
2018-11-15
Acceptance date:
2018-11-11
DOI:
EISSN:
1460-2083
ISSN:
0964-6906
Pmid:
30445560


Language:
English
Pubs id:
pubs:944208
UUID:
uuid:3d0ff851-00cd-4820-bbf2-3d4cc2d1621f
Local pid:
pubs:944208
Deposit date:
2018-12-07

Terms of use



Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP